2017
Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial
Schneider T, Johns C, Palumbo M, Murphy K, Cahill K, Laidlaw T. Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial. The Journal Of Allergy And Clinical Immunology In Practice 2017, 6: 825-831. PMID: 29133219, PMCID: PMC5945343, DOI: 10.1016/j.jaip.2017.10.011.Peer-Reviewed Original ResearchConceptsAspirin-exacerbated respiratory diseaseUrinary leukotriene EDietary interventionLeukotriene ERespiratory diseaseTreatment of AERDDietary fatty acid modificationAsthma Control Questionnaire scoreNasal Outcome Test (SNOT-22) scoresAdjunct treatment optionProspective pilot trialPatient-reported questionnaireFatty acid consumptionTreatment of aspirinOutcome Test scoresAdult patientsAdverse eventsLung functionPrimary outcomeClinical efficacyVital capacityTreatment optionsWomen's HospitalIntervention periodPilot trial
2016
Automated identification of an aspirin-exacerbated respiratory disease cohort
Cahill K, Johns C, Cui J, Wickner P, Bates D, Laidlaw T, Beeler P. Automated identification of an aspirin-exacerbated respiratory disease cohort. Journal Of Allergy And Clinical Immunology 2016, 139: 819-825.e6. PMID: 27567328, PMCID: PMC5266739, DOI: 10.1016/j.jaci.2016.05.048.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlgorithmsAsthma, Aspirin-InducedComputational BiologyCyclooxygenase InhibitorsFemaleHumansMaleMiddle AgedNasal PolypsConceptsAspirin-exacerbated respiratory diseaseAllergist/immunologistElectronic health recordsPositive predictive valueEHRs of patientsPredictive valueHigh positive predictive valueAnti-inflammatory drugsAERD diagnosisChart reviewNasal polyposisClinical featuresCohort ANasal polypsPartners HealthCare SystemPatient RegistryPatient notesUndiagnosed casesDisease cohortRespiratory diseaseRespiratory reactionsInformatics algorithmClinical expertsSearch termsHealth records
2015
Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease
Lee-Sarwar K, Johns C, Laidlaw T, Cahill K. Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. The Journal Of Allergy And Clinical Immunology In Practice 2015, 3: 449-451. PMID: 25634222, PMCID: PMC4426242, DOI: 10.1016/j.jaip.2015.01.007.Peer-Reviewed Original Research
2014
Elevated Total Serum IgE in Nonatopic Patients with Aspirin-exacerbated Respiratory Disease
Johns C, Laidlaw T. Elevated Total Serum IgE in Nonatopic Patients with Aspirin-exacerbated Respiratory Disease. American Journal Of Rhinology And Allergy 2014, 28: 287-289. PMID: 25197914, DOI: 10.2500/ajra.2014.28.4054.Peer-Reviewed Original ResearchConceptsAspirin-exacerbated respiratory diseaseElevated total serum IgETotal serum IgESubset of patientsSerum IgERespiratory diseaseNonsteroidal anti-inflammatory drugsOral aspirin challengeHistory of atopyAbsence of atopyRecurrent nasal polypsSubgroup of patientsAllergic-like reactionsAnti-inflammatory drugsPositive test resultsAspirin challengeNonatopic patientsCommon aeroallergensSamter's triadEntire cohortNasal polypsMean bloodAtopyPatientsClinical relevance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply